ALT
SHORT CANDIDATEMeanRevComposite
26.90
Technical
26.10
Fundamental
27.10
Rank
—
Price
2.88
Hurst
0.35
As of
Aug 14, 2026
Daily
Altimmune, Inc.
HealthcareBiotechnologyAltimmune is a biopharmaceutical firm developing treatments for severe hepatic conditions. Its primary candidate, pemvidutide, is a dual-action GLP-1/glucagon receptor agonist currently undergoing Phase 3 testing for metabolic dysfunction-associated steatohepatitis, alcohol use disorder, and alcohol-related liver disease. Founded in 1997, the company is based in Gaithersburg, Maryland.
Market cap
$630.2M
P/E (trailing)
—
P/E (forward)
-4.85
PEG ratio
32.62
Dividend yield
—
Beta
0.18
52w range
2.56 – 6.44
Return on equity
-28.88%
Profit margin
0.00%
Revenue growth
—
Earnings growth
—
Price history
1Y: 3.24 (-16.3%) · range 2.59–6.18
Cycle position
48/ 100 cycle scoreMID-BULL
ENTRYAPPROACHMID-BULLNEAR-TOPEXIT
entry readiness 29 · NOT READY · exit proximity 0
Conviction
23/ 100 · maturity 100%
VScore.4014
Buildup.2030
EMA entry setup.2529
Fundamentals.1527
Volume profile
POC
3.00
Price vs POC
+7.9%
Overhead supply
13%
Runway
open sky
Value area 2.75–3.19 · 13% of 120d volume overhead · clean runway
Contributing sources
| Source | Score | Last seen |
|---|---|---|
| short-interest | 1.000 | Aug 31, 2026 |
| squeeze-risk | 1.000 | Aug 31, 2026 |
| earnings-surprise | 0.033 | Sep 10, 2026 |
Forward returns
| Horizon | Return | MFE | State |
|---|---|---|---|
| 20d | +5.14% | +9.97% | 14/20d |
| 40d | +5.14% | +9.97% | 14/40d |